TransEnterix (San Diego, CA) a clinical-stage medical device company focused on laparoscopic systems for abdominal surgery, closed a $15M Series B financing. Participants include Aisling Capital, Quaker BioVentures, Intersouth Partners, Synergy Life Science Partners and SV Life Sciences.

NovaSom (Glen Burnie, MD) a commercial-stage medical device company focused on the diagnosis of obstructive sleep apnea, closed a $35M Series F financing. Participants include Safeguard Scientifics, TPG Biotech and Quaker BioVentures.

Neuronetics (Malvern, PA) a commercial-stage medical device company focused on pulsed magnetic field stimulation for non-invasive, non-systemic treatment of depression, closed a $30M Series E financing. Participants include Polaris Venture Partners, Pfizer Venture Investments, Investor Growth Capital, New Leaf Venture Partners, Interwest Partners, Three Arch Partners, Quaker BioVentures and Onset Ventures.

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage pharmaceutical company developing novel small molecule drugs to treat cancer, closed a $6M Series C financing bringing the total round to $43M. Participants include Nextech Invest, Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, Vertical Group and Amgen Ventures.

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company developing novel small molecule drugs to treat cancer, closed a $23M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, The Vertical Group and Amgen Ventures.

Celator Pharmaceuticals (Princeton, NI) a clinical-stage small molecule company focused on acute myeloid leukemia and colorectal cancer, closed a $20M Series D financing. Participants have included Thomas McNerney & Partners, BDC Venture Capital, Domain Associates, GrowthWorks Capital, Quaker BioVentures, TL Ventures and Ventures West.

TetraLogic Pharmaceuticals (Malvern, PA) a preclinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $32M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and Vertical Group.

Regado Biosciences (Basking Ridge, NJ) a clinical-stage biopharmaceutical company with an aptamer platform drug-antidote pairing system focused upon the anticoagulant market, closed a $40M Series D financing. Participants include Edmond de Rothschild Investment Partners, Domain Associates, Quaker Bioventures, Aurora Funds and Caxton Advantage Life Sciences Fund. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

TransEnterix (Durham, NC) a development-stage medical device company focused on a laparoscopic surgical platform for minimally invasive abdominal surgeries, closed a $55M Series B financing. Participants include Aisling Capital, Intersouth Partners, Quaker BioVentures, SV Life Science Advisers, Synergy Life Science Partners and Parish Capital Advisors. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Tarsa Therapeutics (Boonton, NJ) a clinical stage small molecule company focused on osteoporosis closed a $24M Series A financing. Participants include MVM Life Science Partners, Quaker BioVentures and Novo Ventures. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Sleep Solutions (Glen Burnies, MD) a commercial-stage medical device and diagnostics company focused on obstructive sleep apnea, closed a $20M Series F financing. Participants include Quaker BioVentures, Johnson & Johnson Dev Corp., TPG Growth, MedVenture Associates, Emergent Ventures and Lava Ventures.